AstraZeneca’s Imfinzi in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer.
[Astrazeneca]
